First da­ta for Lil­ly's RNA treat­ment for heart dis­ease point to long-term dura­bil­i­ty in tiny group of pa­tients

PHILADEL­PHIA — Eli Lil­ly’s in­ves­ti­ga­tion­al RNA si­lenc­ing drug low­ered lev­els of lipopro­tein(a) in an ear­ly-stage study. El­e­vat­ed lev­els of Lp(a) have been as­so­ci­at­ed with a high­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.